CARNA BIOSCIENCES, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2003-04-10
- Employees
- 67
- Market Cap
- -
- Website
- http://www.carnabio.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell MalignancyChronic Lymphocytic LeukemiaNon-Hodgkin LymphomaWaldenstrom MacroglobulinemiaFollicular LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Carna Biosciences, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05602363
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
News
No news found